Sun Pharma Q4 results: Consolidated net profit declines 37% to Rs 399 cr; revenue up 14% to Rs 8,185 cr

New Delhi: Pharma major Sun Pharmaceutical Industries on Wednesday reported a 37.12 percent decline in its consolidated net profit to Rs 399.84 crore for the quarter ended March 2020, mainly on account of one time exceptional loss. The company had posted a net profit of Rs 635.88 crore in the same period previous fiscal, Sun Pharma said in a BSE filing. Consolidated revenue from operations stood at Rs 8,184.94 crore for the quarter under consideration as against Rs 7,163.92 crore in the same period a year ago, it added.

#4QWithCNBCTV18 | Sun Pharma Q4: Tax expense at Rs 83.1 cr vs tax credit of Rs 28.8 cr (YoY) pic.twitter.com/QqzdESCYS7

— CNBC-TV18 (@CNBCTV18Live) May 27, 2020

The company had a one-time exceptional loss of Rs 260.64 crore in the quarter ended March 2020, the filing said. For the fiscal ended March 2020, the net profit of the company was at Rs 3,764.93 crore as against Rs 2,665.42 crore in the previous fiscal, Sun Pharma said. The revenue from operations for the fiscal ended March this year stood at Rs 32,837.50 crore. It was Rs 29,065.91 crore the year-ago fiscal, it added. The board has recommended payment of a dividend of Re 1 per equity share of Re 1 each for the year ended 31 March, 2020, Sun Pharma said. Shares of Sun Pharmaceutical Industries were closed at Rs 450.55 per scrip on the BSE, down 1.85 percent from its previous close.